La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
80 hedge funds and large institutions have $163M invested in La Jolla Pharmaceutical Company in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 23 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
4% less funds holding
Funds holding: 83 → 80 (-3)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
25% less call options, than puts
Call options by funds: $340K | Put options by funds: $455K
43% less capital invested
Capital invested by funds: $286M → $163M (-$122M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.9M |
| 2 |
VMI
VHCP Management III
New York
|
+$6.54M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.83M |
| 4 |
Millennium Management
New York
|
+$3.67M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$41M |
| 2 |
Jennison Associates
New York
|
-$30.8M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$12.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.96M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
-$1.41M |
LJPC Hedge Fund Activity: Q1 2019 in Review
80 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2019, worth a combined $163M — down 43% from $286M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LJPC and 20 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 22 added.
The largest buyer was Tang Capital Management, adding an estimated $6.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $41M sold.
- 80 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2019, down from 83 in Q4 2018.
- Funds reported $163M of La Jolla Pharmaceutical Company stock for Q1 2019, down 43% quarter-over-quarter.
- 20 funds opened new La Jolla Pharmaceutical Company positions in Q1 2019 and 23 closed out, a net change of -3 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2019 was Tang Capital Management, an estimated $6.9M added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2019 was Perceptive Advisors, an estimated $41M sold.
Based on aggregated 13F filings for Q1 2019.